<a href="https://www.fiercebiotech.com/biotech/seaport-hemab-chart-courses-180m-ipos-fund-depression-clotting-candidates" hreflang="en">Seaport, Hemab chart courses for $180M IPOs to fund depression, clotting candidates</a>
Seaport Therapeutics and Hemab Therapeutics are both planning to raise approximately $180 million each through IPOs to fund their respective drug candidates for depression and clotting disorders. Seaport aims to advance its depression treatment SPT-300, while Hemab focuses on developing its bispecific antibody sutacimig for bleeding disorders.
The resurgence of biotech IPOs is highlighted by Seaport and Hemab Therapeutics, both aiming to raise around $180 million to advance their respective drug candidates. Seaport is focusing on depression treatments using its Glyph platform to enhance drug bioavailability, while Hemab is targeting clotting disorders with its bispecific antibody sutacimig. This indicates a renewed investor appetite and potential opportunities in neuropsychiatric and rare disease markets, suggesting a favorable climate for investment in innovative biotech solutions.